Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T.A. van der Graaf, Peter Hohenberger, Rachel Hodge et al.|The Lancet|2012Cited by 2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Jaap Verweij et al.|The Lancet Oncology|2014Cited by 1.2k
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Luis Paz‐Ares et al.|The Lancet Oncology|2022Cited by 738
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trialSylvie Bonvalot, Rick L. Haas, Alessandro Gronchi et al.|The Lancet Oncology|2020Cited by 482
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389